Celestica vs. SpaceX: Which Aerospace Stock is the Better Buy Now?

The article favors SpaceX (SPCX), citing projected 2026 sales growth of 136.2% and a 350% improvement in EPS estimates over the past 60 days; it also notes SpaceX’s $60 billion all-stock agreement to acquire Anysphere. The outlook is tempered by a multi-year, capital-intensive AI investment cycle and a 22.53 forward price-to-sales ratio, versus 1.36 for Celestica (CLS). CLS is projected to grow 2026 sales and EPS by 64.3% and 87.1%, respectively, but its EPS estimate edged down over the past 60 days; the article cites its margin pressures and gives it a Zacks Rank #3 (Hold), compared with SpaceX’s #2 (Buy).

Analysis

The key market distinction is earnings quality, not headline growth: CLS converts AI infrastructure demand into manufacturing revenue, where customer concentration, pricing power and utilization determine whether rapid sales growth becomes durable EPS. If growth requires price concessions or added working capital, high revenue estimates can coexist with disappointing cash conversion. FLEX and SANM may share the same AI-server demand pool, but added EMS capacity can also intensify bidding and cap margins across the group.

SPCX combines operating businesses with substantial AI investment optionality. That optionality can justify a premium only if spending produces measurable utilization, recurring revenue and improving segment economics; otherwise investors may capitalize speculative projects at a software-like multiple while funding them with infrastructure-scale capital. The cited 22.53x forward sales makes estimate quality and dilution/financing disclosures especially important. Treat the reported acquisition and earnings-revision data as claims to verify against filings, not established value creation.

Near term, momentum and upward revisions can keep SPCX expensive. Over 1–3 months, monitor reported bookings, margins and cash conversion at CLS, and SPCX disclosure on deal terms, capex, segment losses and financing. Over 6–18 months, the upside case for SPCX requires AI/compute integration to monetize; the downside is investment intensity outpacing recurring cash generation. Contrarian angle: CLS’s lower sales multiple is not automatically cheap, but the valuation gap may overprice SPCX’s unproven AI adjacency. No aggressive outright short while revisions are rising.

Key Decisions for Investors

• Avoid chasing SPCX solely on estimate momentum. Verify the reported acquisition terms and revisions, then track capex, segment-adjusted EBITDA, dilution/financing and recurring revenue; failure to show improving unit economics would weaken the premium-growth thesis.
• Prefer CLS as the more valuation-sensitive exposure only if upcoming results confirm AI infrastructure demand is translating into gross-margin stability and cash conversion. Falsifier: growth accompanied by margin deterioration, weaker guidance or rising working-capital needs.
• Consider a small, risk-controlled CLS-long/SPCX-short relative-value position only after confirming current prices, liquidity, borrow and comparable forward estimates; size for the possibility that SPCX momentum widens the valuation spread before fundamentals catch up. Reassess if CLS raises margin guidance or SPCX demonstrates sustained AI/compute monetization.
• Watch FLEX and SANM results and order commentary as checks on whether AI-server demand is broad-based or concentrated, and whether EMS competition is pressuring pricing.